NME: Bendamustine (Treanda), an alkylating agent, was approved on March 20, 2008, for the treatment of chronic lymphocytic leukemia (CLL).
Bendamustine, an alkylating agent, is a bifunctional mechlorethamine derivative. This agent's exact mechanism of action is unknown. Bendamustine was approved on March 20, 2008, for the treatment of chronic lymphocytic leukemia (CLL).
Efficacy. The efficacy of bendamustine was evaluated in an open-label, randomized, controlled, multicenter trial that enrolled 301 treatment-naïve patients with Binet stage B or C (Rai stages I–IV) CLL that required treatment. Patients were randomized to receive intravenous (IV) bendamustine 100 mg/m2 via a 30-minute infusion on Days 1 and 2 or oral chlorambucil 0.8 mg/kg on Days 1 and 15 of each 28-day cycle. The efficacy end points were objective response rate (ORR) and progression-free survival (PFS). Patients treated with bendamustine demonstrated an ORR of 59% (95% CI, 51.03%–66.62%) versus 26% (95% CI, 18.64%–32.71%) among patients who received chlorambucil (P<.0001). Median PFS among bendamustine-treated patients was 18 months (95% CI, 11.7–23.5) versus 6 months (95% CI, 5.6–8.6) among patients treated with chlorambucil (HR=0.27; 95% CI, 0.17–0.43; P<.0001).
Safety. Bendamustine treatment is associated with myelosuppression. Infections have been reported in patients treated with bendamustine; some of these infections have been associated with hospitalization, septic shock, or death. Bendamustine-treated patients have experienced infusion reactions. Rarely, severe anaphylactic and anaphylactoid reactions have occurred. Bendamustine therapy has been associated with tumor lysis syndrome. Skin reactions such as rash, toxic skin reactions, and bullous exanthema have been reported in patients treated with bendamustine. The most common adverse events associated with bendamustine treatment include neutropenia, pyrexia, thrombocytopenia, nausea, anemia, leukopenia, and vomiting.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More